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Florence, Florence 50139, Italy; and The Wellcome Trust Sanger Institute (D.J.T., Y.X., C.T.-S.), Wellcome
Trust Genome Campus, Hinxton, Cambridge CB10 1SA, United Kingdom
Context: TSPY1 is a tandemly-repeated gene on the human Y chromosome forming an array of
approximately 21–35 copies. The testicular expression pattern and the inferred function of the
TSPY1 protein suggest possible involvement in spermatogenesis. However, data are scarce on
TSPY1 copy number variation in different Y lineages and its role in spermatogenesis.
Objectives:We sought to define: 1) the extent of TSPY1 copy number variationwithin and among
Y chromosome haplogroups; and 2) the role of TSPY1 dosage in spermatogenic efficiency.
Materials andMethods:A total of 154 idiopathic infertilemen and 130 normozoospermic controls
fromCentral Italywereanalyzed.Weusedaquantitative PCRassay tomeasureTSPY1 copynumber
and also defined Y haplogroups in all subjects.
Results:We provide evidence that TSPY1 copy number shows substantial variation among Y hap-
logroups and thus that population stratification does represent a potential bias in case-control
association studies. We also found: 1) a significant positive correlation between TSPY1 copy num-
ber and sperm count (P 0.001); 2) a significant difference in mean TSPY1 copy number between
patients and controls (28.4  8.3 vs. 33.9  10.7; P  0.001); and 3) a 1.5-fold increased risk of
abnormal sperm parameters in men with less than 33 copies (P  0.001).
Conclusions: TSPY copy number variation significantly influences spermatogenic efficiency. Low
TSPY1 copy number is a new risk factor for male infertility with potential clinical consequences.
(J Clin Endocrinol Metab 94: 4016–4022, 2009)
The human testis-specific protein Y-encoded 1 (TSPY1)genewasoriginally identifiedasageneon the short arm
of thehumanYchromosomewithatestis-specificexpression
pattern (1, 2). Themajority ofTSPY1 copies are arranged in
20.4 kb tandemly repeated units, each containing one copy
ofTSPY1 and one of theCYorf16 pseudogene transcription
unit, forming an approximately 400- to 800-kb cluster
(DYZ5) corresponding toapproximately20–40genecopies
on proximal Yp (3, 4). Such a structure is highly unusual in
thehumangenome:only12protein-codinggenesarepresent
in tandem clusters withmore than three copies, and none of
theothers showsmore than16copies in thecurrentassembly
(5). The TSPY1 cluster lies within the critical region for the
gonadoblastoma locus on the Y chromosome (GBY) that
predisposes dysgenetic gonads of intersex patients to go-
nadoblastoma development (6, 7), but the biological role of
TSPY1 is otherwise poorly understood.
TSPY1 is amember of a protein superfamily that includes
SETandNAP,which are activating factors of the replication
process, as binding-partners of cyclin B (8, 9). Various
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TSPY1 isoforms are generated by alternative splicing events
of transcripts originating fromthe same transcriptional units
(10, 11). Full-length TSPY1 is expressed in the normal testis
predominantly in spermatogonia and at a low level in pri-
mary spermatocytes, indicating a major role in the mitotic
division of early germ cells (9). The role of theminorTSPY1
transcripts, which seem to be preferentially expressed in
round spermatids, remains to be elucidated (12). Thus, the
expression pattern of full-length TSPY1 suggests a potential
role in male germ cell development as a proliferation factor
during spermatogenesis (2, 9).
The number of TSPY1 gene copies observed in the two
main studies ranged from18 to 47 and from23 to 64 copies,
respectively (13,14); thisvariation is likely tobegeneratedby
unequal sister chromatid exchange (8, 15). Maintenance of
a minimum copy number through selection is suggested by
the evolutionary conservationofmultiple copies of the geneon
theY chromosomes of othermammals (16, 17) andby limited
variation in copy number in humans, with pronouncedmodes
and few excursions to lowor high numbers of copies (18). The
natureof theputative selective force remains entirely unknown
but seemsmost likely to be related to spermatogenesis.
Thus far, only one study has addressed the question of
whetherornotTSPY1 copynumber variationmay influence
spermatogenesis and reported an association between in-
creased TSPY1 copy number and infertility (19). The inter-
pretation of these results, however, is difficult for two rea-
sons: 1) the quantification method employed was unable to
provide an exact TSPY1 copy number because it was not
validated against a gold standard method (e.g. pulsed-field
gel electrophoresis); and 2) the size of the study population
was small, and Y haplogroup (hg) matching was performed
only in a minority of cases, so differences might reflect hg
stratification.
We have now reinvestigated the role of TSPY1 dosage in
spermatogenic efficiency by setting up a validated method
able to provide an absolute number of TSPY1 copies and
applying it to a large study population. For this purpose
we compared TSPY1 copy number between men with
normozoospermia (controls) and a heterogeneous
group of idiopathic infertile men (cases) with different
grades of spermatogenic failure. We controlled for Y
lineage effects by determining the hg of participants and
thus also provide the largest analysis to date of TSPY1
copy number variation in individuals belonging to six
different Y lineages.
Subjects and Methods
Subjects
The study population consisted of a total of 284 subjects: 154
idiopathic infertile patients, and 130 normozoospermic men. The
studywas approved by the local ethics committee. Infertile patients
includedinthestudywereseekingcompleteandrologicaldiagnostic
work-up for couple infertility at theAndrologyUnit and theUnit of
Physiopathology of Reproduction of the University Hospital Car-
eggi (Florence, Italy). Infertile patients were selected on the basis of
a comprehensive andrological examination including medical his-
tory, semen analysis, scrotal ultrasound, hormone analysis, karyo-
type and Y chromosome microdeletion screening. Patients with
mono- or bilateral cryptorchidism, varicocele grades 2 and 3, ob-
structive azoospermia, recurrent infections, iatrogenic infertility,
hypogonadotrophic hypogonadism, karyotype anomalies, Y chro-
mosomemicrodeletions including partial deletions of theAZFc re-
gion, and partial AZFc duplications and patients with non-Italian
origin were excluded.
According to the three major sperm parameters, the infertile
group could be divided as follows: azoospermia in 36 patients;
cryptozoospermia (1 million spermatozoa/ml) in 13 patients;
severe oligozoospermia (1–5 million spermatozoa/ml) in 55 pa-
tients; moderate oligozoospermia (5–20 million spermatozoa/
ml) in 36 patients; astheno and/or teratozoospermia in 14 pa-
tients. The mean sperm concentrations in patients and controls
were 4.0 4.7 106 and 83.9 53.6 106 sperm/ml, respec-
tively. The mean total sperm numbers in patients and controls
were 14.5 19.8 106 and 271.5 163.0 106 spermatozoa,
respectively.Controlswere selectedon the basis of normal sperm
parameters (sperm count,motility, andmorphology) defined ac-
cording to theWorldHealthOrganization criteria (20). Samples
were collected using approved protocols, and the informed con-
sent of all individuals was obtained.
Estimation of TSPY1 copy number
RelativeTSPY1 copynumberwasdeterminedbyquantitative
PCR, using a region of the single copy PMP22 gene as a control
locus as described (21). Absolute numbers of TSPY1 genes were
estimated by reference to DNA samples in which copy number
was known from sizemeasurement of the hybridizingXbaI frag-
ment in pulsed-field gel analysis (13, 22).
Detection of the AMELY gene deletion
All patients and controls were screened for AMELY gene
deletion by PCRamplification of specific Sequence Tagged Sites:
sY70 (GenBank accession no. G66517) and sY276 (GenBank
accession no. G38362). The amplified products were run on an
agarose gel, and all showed the presence of both fragments, in-
dicating that AMELY was present.
Y hg definition
To exclude recruitment bias, care was taken in the ethnic and
geographic matching of the patients and controls. All patients
and controls were asked for their paternal and maternal origin
and were included only if they had Central Italian ancestry on
both sides. The subjects were genotyped for six binary markers
defining eight hgs (including paragroups): hgs A, DE, J, K*(xN, P),
N, P*(xR1a), R1a, and the remaining Y*(xA, D, E, J, K) chro-
mosomes. Y chromosome haplotyping was performed as previ-
ously described for the YAP, M9, SRY-1532, 92R7, LLY22 g,
and 12f2 polymorphisms (23). Polymorphisms were visualized
by size or presence/absence of fragments (YAP, 12f2) or restric-
tion enzyme digestion pattern for: M9 (HinfI), SRY-1532
(DraIII), 92R7 and LLY22 g (HindIII). Further analysis showed
that most P*(xR1a) chromosomes fell into R1b1b (M269-de-
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rived), but theP*(xR1a) classification is usedherebecauseM269
data are not available for all samples.
Statistical analysis
Statistical analysis was performed using the statistical pack-
age SPSS for Windows (version 15.0.1; SPSS Inc., Chicago, IL).
Median and mean values between groups were compared using
a nonparametric Mann-Whitney U test and Student’s t test (in
case of normal distributions), respectively. Correlation between
TSPY1 copy number and sperm count was ascertained by Spear-
man’s correlation test. The cutoff value of TSPY1 copy number
for the comparison of different subgroups was defined on the
basis of receiver operating characteristic curve analysis. Differ-
ences in the incidenceof subjectswithTSPY1 copynumberabove
andbelow the selected cutoff between patients and controlswere
evaluated using the Fisher’s exact test. A P value of 0.05 was
considered statistically significant for each test.
Results
Y hg distribution in the study population and
sperm count in men belonging to distinct hgs
We performed Y hg analysis in the entire study popu-
lation. Patients and controls showed a similar Y hg dis-
tribution with the exception of the low-frequency hg
K*(xN, P) (Table 1). Hgs A and N were not found in our
study population at all, whereas hgR1awas found only in
one subject, whowas excluded from subsequent analyses.
The mean sperm concentration of normozoospermic
men of hg K*(xN, P) was significantly lower than of those
belonging to hgs Y* and DE (P  0.04 and P  0.001,
respectively). However, when total sperm counts were
compared, no significant differences were found between
subjects belonging to these Y hgs.
TSPY1 copy number variation and Y hgs
The number of TSPY1 copies varied substantially
within each hg (Table 2). Although the variance within
different hgs was similar, the mean TSPY1 copy number
differed significantly between the following Y lineages: 1)
hg P*(xR1a) vs. hg J (29.7  8.5 vs. 33.7  11.4 copies;
P 0.025); and 2) hg P*(xR1a) vs. hg DE (29.7 8.5 vs.
34.6  11.1 copies; P  0.005).
TSPY1 copy number in patients vs. controls
In our study population, the number of TSPY1 gene
copies ranged from11 to 72 (from11 to 54 in patients and
from14 to 72 in controls), but themajority of subjects had
a TSPY1 copy number within the range 21–35 (67% of
patients and62%of controls).Weobserved a shift toward
TABLE 1. Sperm characteristics (expressed as mean  SD of sperm concentration and total sperm number) of
patients and controls stratified by Y-chromosome hg
Y hg
Patients (n  154) Controls (n  130)
n (%)
Sperm
concentration
(n  106/ml)
Total sperm no.
(n  106) n (%)
Sperm
concentration
(n  106/ml)
Total sperm no.
(n  106)
Y*(xA, D, E, J, K) 37 (24) 3.2  3.9 11.0  15.0 31 (23.9) 87.1  64.8 257.7  182.5
P*(xR1a) 76 (49.4) 4.3  5.3 16.1  22.7 64 (49.2) 83.5  53.7 270.0  160.9
J 20 (13) 3.7  4.7 13.7  15.8 12 (9.2) 97.8  56.3 312.9  196.5
DE 19 (12.3) 4.3  3.7 16.3  20.7 16 (12.3) 84.7  30.1 298.6  135.9
K*(xN,P) 1 (0.65) 2.9 17.7 7 (5,4) 47.0  16.6 213.9  72.5
R1a 1 (0.65) 0.5 1.7 0 (0)
TABLE 2. TSPY1 copy number distribution and comparison of mean  SD TSPY1 copy number in different Y hgs
with P values referred to hg P*(xR1a)
Y hg
Study population (n  284)
Patients
(n  154) Controls (n  130)
n
TSPY1 copy
no. Range Pa n
TSPY1 copy
no. n
TSPY1 copy
no. Pb
Y*(xA, D, E, J, K) 68 30.7  10.3 11–62 ns 37 27.9  8.8 31 34.1  11.1 0.05
P*(xR1a) 140 29.7  8.5 13–58 76 27.2  7.3 64 32.6  9.0 0.001
J 32 33.7  11.4 18–72 0.05 20 30.7  8.5 12 38.7  14.1 ns
DE 35 34.6  11.1 12–66 0.01 19 32.5  10.0 16 37.1  12.2 ns
K*(xN,P) 8 28.4  12.1 19–56 ns 1 22 7 29.3  12.8 ns
Comparison of mean TSPY1 copy numbers between patients and controls is shown separately for each Y hg with the respective P values. ns, Not
significant.
a P value relative to mean TSPY1 copy number in the different Y-hg vs. hg P*(xR1a).
b P value relative to mean TSPY1 copy number in patients vs. controls, within each Y-hg.
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higher copy numbers in controls and toward lower copy
numbers in patients (Fig. 1A). The mean TSPY1 copy
number was significantly lower in the patient group than
in the controls (28.4  8.3 vs. 33.9  10.7; P  0.001).
The risk of an individual with less than 33 copies being a
patientwith impaired spermparameters rather thana con-
trol was significantly increased [odds ratio (OR)  1.5;
95% confidence interval (CI), 1.2–1.8; P  0.001). We
also calculated the risk for being a man with impaired
sperm production after removing the 14 pure astheno/
teratozoospermic men (i.e. those men who had a normal
total sperm count but abnormal motility and/or morphol-
ogy): OR  1.5; 95% CI, 1.3–1.8.
To investigate whether or not the significant difference
observed in the whole study population was limited to a
specific hg, we performed—within each hg—a compari-
son of the mean TSPY1 copy number in patients vs. con-
trols (Table 2). The mean TSPY1 copy number in patients
was lower in each hg compared with controls, although a
significant difference was observed only in hg P(R1a)
(27.2  7.3 vs. 32.6  9.0 copies; P  0.001) and in hg
Y*(xA, D, E, J, K) (27.9 8.8 vs. 34.1 11.1 copies; P
0.012). The lack of significance in the remaining Y hgs
may be due to the low number of subjects.
Because hg P*(xR1a) showed the most significant dif-
ference between controls and patients we calculated the
OR for this specific subgroup with the same threshold
value ofTSPY1 33 copies (OR 1.5; 95%CI, 1.2–2.0;
P 0.001). The distribution ofTSPY1 copy number in hg
P*(xR1a) is reported in Fig. 1B.
Effect of TSPY1 gene copy number variation on
spermatogenesis
Correlation between the TSPY1 copy number and
sperm count
We found a positive correlation between theTSPY1 copy
number and sperm count, both in the whole study popula-
tion (Rho coefficient  0.331, P  0.001; and Rho coeffi-
cient 0.315, P 0.001 for sperm concentration and total
sperm count, respectively) and separately in controls (Rho
coefficient0.282,P0.001;andRhocoefficient0.178,
P  0.043 for sperm concentration and total sperm count,
respectively) and in patients (Rho coefficient  0.190, P 
0.018; and Rho coefficient  0.214, P  0.008 for sperm
concentration and total sperm count, respectively) (Fig. 2).
Comparison of sperm concentration and total sperm
count within subgroups defined on the basis of
TSPY1 copy number
To investigate further the effect ofTSPY1 copy number
variation on spermatogenesis, patients and controls were
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FIG. 1. TSPY1 copy number ranges in patients and controls in the
whole study population (A) and subjects belonging to hg P*(xR1a) (B).
The majority of subjects have a TSPY1 copy number within the range
21–35.
FIG. 2. Scatter plots between TSPY1 copy number and total sperm
count in the whole study population (A), patients (B), and controls (C).
Spearman’s correlation coefficients are reported in the text.
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grouped into quartiles on the basis of their TSPY1 copy
number. The comparison of the median sperm concentra-
tion and total sperm count within quartiles is reported in
Table 3. Sperm concentration and total sperm count were
higher in the fourth quartile (with the highestTSPY1 copy
numbers) than in the first quartile, and reached statistical
significance for sperm concentration in both groups.
We compared sperm concentration and total sperm
count within patients and controls, above and below the
threshold value used for the calculation of OR, i.e.
TSPY1 33. The analysis further confirmed that subjects
with less than 33TSPY1 copy number have a significantly
lower sperm production (Fig. 3).
Discussion
The Y chromosome is enriched for genes involved in sper-
matogenesis, and its structure predisposes to it deletions
andduplications, and thus to variation in the copynumber
of these genes. During the past 15 yr, much emphasis has
been given to theAZF (azoospermia factor) regions on the
long arm of the Y chromosome. The complete loss ofAZF
region(s) by deletion causes impairment of spermatogen-
esis and represents the most frequent known molecular
genetic cause of male infertility (3, 24). In addition,
partial loss of the AZFc region (gr/gr deletion) is a sig-
nificant genetic risk factor for oligozoospermia (25,
26). We now provide evidence for a significant effect of
the copy number of TSPY1, a multicopy gene situated
on Yp, on spermatogenesis.
Because the Y chromosome shows marked population
stratification and data in the literature concerning TSPY1
copy number variation in different Y lineages are scarce,
we first investigated whether the different Y hgs that are
common in the Italian population showed different
TSPY1 copy numbers. Based on the analysis of 47 Y hgs,
Repping et al. (14) had previously observed little variation
in TSPY1 copy number within and between Y hgs,
whereas an earlier analysis limited to the few hgs that
could be identified in 1994 observed more variation
withinhgs (13).Wenowreport substantial variation in the
number ofTSPY1 copieswithin the six commonYhgs and
paragroups present in our studypopulation.The variation
was especially high inhg J (from18 to72 copies), although
this was not significantly greater than in the other Y lin-
eages. In all hgs we observed a peak of frequencies for
TSPY1 copy number in the range 21–35, which may in-
dicate an optimal range of copy number. Interestingly, hg
P (the most frequent hg in Central Italy) contained signif-
icantly lower TSPY1 copy numbers than hgs J and DE; a
P vs. DE difference is in line with the observations of
Mathias et al. (13) on equivalent hgs then named 1 and 4,
which were made using a different method (pulsed-field
gel electrophoresis) on a smaller studypopulation (20 sub-
jects belonging to hg DE vs. 31 hg P).
Our finding indicates that the analysis of TSPY1 copy
number variation in the context of case-control associa-
tion studies is susceptible to stratification bias. This ob-
servation implies that data from unmatched study pop-
TABLE 3. Comparison of the median values (with the respective ranges) of sperm concentration and total sperm
count among quartiles I and IV in the two study populations (patients and controls)
I Quartile IV Quartile
TSPY1
range (n)
Sperm
concentration
(n  106/ml)
Total sperm no.
(n  106)
TSPY1
range (n)
Sperm
concentration
(n  106/ml)
Total sperm no.
(n  106) Pa Pb
Patients 11–22 (n  37) 0.9 (0–14.8) 1.7 (0–74) 33–54 (n  38) 4.0 (0–27) 14.3 (0–135) 0.012 0.007
Controls 14–25 (n  29) 53 (28–188) 224.0 (37.8–570) 40–72 (n  36) 80.0 (22–329) 285.7 (51–730.8) 0.001 0.041
a P value obtained comparing the median sperm concentration, within patients and controls, between quartiles I and IV.
b P value obtained comparing the median total sperm count, within patients and controls, between quartiles I and IV.
FIG. 3. Comparison of the median values of sperm concentration and
total sperm number above and below the selected threshold value (33
TSPY1 copies) used for the calculation of OR, within patients (A) and
controls (B). *, P  0.05; **, P  0.001.
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ulations may not provide reliable information. The
distribution of Y hgs in controls and patients in our study
was similar, leading us to two major conclusions: 1) no Y
hg predisposed to impaired spermatogenesis to a detect-
able extent; and 2) TSPY1 copy number differences be-
tween controls and cases were independent of the Y back-
ground. Concerning the former, the relationship between
Y background and reproductive fitness has been contro-
versial, which may partly be related to study design biases
(small sample size, inappropriate inclusion criteria for pa-
tients and controls) (27). This is the first study of a large
European sample in which Y hg distribution was com-
pared between normozoospermic controls and idiopathic
infertile men. The lack of a Y hg predisposing to impaired
sperm production in our study population, together with
the lack of significant differences in total sperm counts of
menbelonging todifferentYhgs, provides strong evidence
on the lack of a significant Y hg effect in the Italian
population.
Concerning our second conclusion, we found a signif-
icantly lower number of TSPY1 copies in infertile men
with abnormal sperm parameters compared with men
with normozoospermia. As emphasized above, this differ-
encewasnot related to adifference in the prevalence of hgs
DE or J—the hgs that have a higher mean TSPY1 copy
number thanP—in the control group.Weobserveda trend
toward lower TSPY1 copy number in the infertile group
within each hg, suggesting that the contraction or expan-
sion responsible for the observed differences between
cases and controls occurs in all Y lineages. Accordingly to
our analysis, the risk of having abnormal sperm parame-
ters was increased 1.5-fold for a man with fewer than 33
TSPY1 copies. Other evidence for a significant contribu-
tionofTSPY1dosage to spermatogenesis included: 1) pos-
itive correlation between sperm count and TSPY1 copy
number in the whole study population and separately in
controls and cases; and 2) significant differences in sperm
production in men with more and less than 33 copies.
Given the link between TSPY1 copy number and sperm
count on the one hand and the difference in mean TSPY1
copy number between hgs on the other, we would expect
to see a TSPY1-dependent relationship between hgs and
sperm count. However, such an effect is small and is ob-
scured by the large variation inTSPY1within each hg, and
would only be detected in substantially larger samples.
Themaintenance of the evolutionarily unstableTSPY1
array across mammalian species suggested that low copy
number must be disadvantageous, and an effect on sper-
matogenesis was likely on the basis of the observed ex-
pression pattern and inferred function of the TSPY1 pro-
tein. Spermatogenesis requires the concerted action of
thousands of genes, all contributing to the efficiency of
spermatogenesis to a different extent. Mutations in genes
essential for spermatogenesis inevitably lead to impaired
spermatogenesis, whereas mutations in genes acting as
tuners/modulators of the efficiency of spermatogenesis
may not necessarily lead to clinically overt conditions (28,
29). Infertility is a complex disorder. Hence, instead of
highly penetrant mutations in single genes (until now very
few causative mutations have been identified), the inter-
action of multiple factors, both genetic and environmen-
tal, with individually small effects is expected to play a
major etiopathogenic role. We have now provided evi-
dence for a link between low TSPY1 copy number and
impaired spermatogenesis. Low TSPY1 copy number
therefore represents a new genetic risk factor for male
infertility with potential clinical consequences and should
be taken into consideration in the context of a multigenic
approach to idiopathic infertility.
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